Physician profile
Jonathan Bunnell
NPI 1629755160
$3,658.79
in general payments reported to CMS, 2019-2025
16 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $656 · 2024: $1,550 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,559 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,129.08 | 2023-2025 | Total30, Clareon, Tryptyr |
| Mallinckrodt Hospital Products INC. | $511.32 | 2024-2025 | Acthar |
| Oyster Point Pharma, INC. | $441.42 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $399.35 | 2024-2025 | Miebo, Xiidra, Infuse |
| Biotissue Holdings INC. | $281.60 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $274.52 | 2024-2025 | Xdemvy |
| Abbvie INC. | $173.81 | 2023-2025 | Alphagan P, Lumigan, Vuity |
| Dompe US, INC. | $93.18 | 2024-2025 | Oxervate |
| Astellas Pharma US INC | $86.04 | 2024-2025 | Izervay |
| Amgen INC. | $65.62 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $50.86 | 2025 | Purified Cortrophin Gel, Iluvien |
| Johnson & Johnson Vision Care, INC. | $33.00 | 2025 | |
| Horizon Therapeutics Plc | $32.21 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $32.16 | 2023 | |
| Sun Pharmaceutical Industries INC. | $28.13 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $26.49 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bunnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.